U.S., February 2025 – CURESPONSE was honored to participate in the Israel Health-Tech Roadshow to the U.S., a strategic initiative led by Startup Nation Central to spotlight the country’s most promising healthcare innovators. Selected from hundreds of companies, CURESPONSE was one of 16 pioneering startups chosen to represent Israeli health-tech excellence across major U.S. healthcare hubs.
The roadshow included high-level engagements in New York City, Chicago, and Philadelphia, where CURESPONSE met with a wide range of stakeholders — including healthcare providers, payers, regulators, and health system leaders — to explore collaboration opportunities and share its unique approach to transforming clinical cancer care.
Highlights from the Roadshow:
- Dozens of high-value meetings with leading U.S. healthcare organizations
- Strong interest in CURESPONSE’s ability to enhance precision and predictability in oncology treatment
- Strategic insights into integrating innovation within complex U.S. health systems and value-based care models
Startup Nation Central summarized the experience as a shift from “pitching to learning,” enabling startups to engage deeply with the realities of the U.S. healthcare market — from integration and regulation to commercialization.
CURESPONSE is redefining the standard of care in oncology.
By testing live tumor samples ex-vivo, CURESPONSE identifies which treatment is most likely to work for each individual patient — before treatment begins. This functional approach moves beyond trial and error, helping providers match patients with the right therapies, improve response rates, and enhance clinical outcomes. As health systems increasingly seek to deliver personalized, data-driven cancer care, CURESPONSE stands out as a powerful enabler of smarter, more effective treatment decisions.
About CURESPONSE
CURESPONSE enables oncologists and healthcare systems to personalize cancer treatment through a unique functional precision platform. By preserving the integrity of tumor samples and assessing response in real-time, CURESPONSE empowers clinical teams to make confident, evidence-based decisions that improve outcomes and reduce unnecessary treatments.